RBC Life Sciences PE Ratio 2010-2015 | RBCL
Current and historical p/e ratio for RBC Life Sciences (RBCL) from 2010 to 2015. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. RBC Life Sciences PE ratio as of May 02, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| RBC Life Sciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-05-01 | 0.00 | 0.00 | |
| 2015-09-30 | 0.60 | $-0.25 | 0.00 |
| 2015-06-30 | 1.20 | $-0.46 | 0.00 |
| 2015-03-31 | 0.52 | $-0.35 | 0.00 |
| 2014-12-31 | 1.30 | $-0.27 | 0.00 |
| 2014-09-30 | 1.66 | $-0.33 | 0.00 |
| 2014-06-30 | 0.75 | $-0.33 | 0.00 |
| 2014-03-31 | 1.28 | $-0.43 | 0.00 |
| 2013-12-31 | 1.55 | $-0.26 | 0.00 |
| 2013-09-30 | 1.49 | $-0.16 | 0.00 |
| 2013-06-30 | 16.00 | $-0.20 | 0.00 |
| 2013-03-31 | 17.00 | $-0.10 | 0.00 |
| 2012-12-31 | 10.00 | $-0.10 | 0.00 |
| 2012-09-30 | 15.00 | 0 | 0.00 |
| 2012-06-30 | 20.00 | 0 | 0.00 |
| 2012-03-31 | 16.38 | 0 | 0.00 |
| 2011-12-31 | 20.00 | $0.10 | 200.00 |
| 2011-09-30 | 28.00 | 0 | 0.00 |
| 2011-06-30 | 30.00 | $0.20 | 150.00 |
| 2011-03-31 | 33.00 | $0.30 | 110.00 |
| 2010-12-31 | 28.00 | $0.30 | 93.33 |
| 2010-09-30 | 37.00 | $0.10 | 370.00 |
| 2010-06-30 | 29.00 | $-0.10 | 0.00 |
| 2010-03-31 | 28.00 | $-0.10 | 0.00 |
| 2009-12-31 | 21.50 | $-0.30 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.000B | $0.000B |
| SciencesRBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. The Company's product line is divided into three categories: wellness products, skin care products and fitness products. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. In certain markets, primarily the U.S. and Canada, the Company markets its products through a network of distributors that are referred to as `Associates`. It also markets its Nutritional Products in certain international markets through license arrangements. | |||